RECIST 1.1 criteria predict recurrence-free survival in advanced ovarian cancer submitted to neoadjuvant chemotherapy

Neoadjuvant chemotherapy plus interval debulking surgery is growing treatment strategy for advanced ovarian cancer patients with unresectable disease. Here, we aimed to assess predictors of surgical unresectability and survival of patients submitted to neoadjuvant chemotherapy plus interval debulkin...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	European journal of obstetrics & gynecology and reproductive biology 2019-06, Vol.237, p.93-99
Hauptverfasser:	Bogani, Giorgio, Matteucci, Laura, Tamberi, Stefano, Ditto, Antonino, Sabatucci, Ilaria, Murgia, Ferdinando, Arcangeli, Valentina, Maltese, Giuseppa, Comerci, Giuseppe, Stefanetti, Marco, Sonetto, Cristina, Calareso, Giuseppina, Marchiano, Alfonso, Chiappa, Valentina, Lorusso, Domenica, Raspagliesi, Francesco
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Chemotherapy, Adjuvant Cytoreduction Surgical Procedures Disease-Free Survival Female Humans Interval debulking surgery Middle Aged Neoadjuvant chemotherapy Neoadjuvant Therapy Ovarian cancer Ovarian Neoplasms - drug therapy Ovarian Neoplasms - mortality Ovarian Neoplasms - surgery Prognosis RECIST Response Response Evaluation Criteria in Solid Tumors Retrospective Studies Survival Rate Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!